Cethromycin

Cethromycin
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
Pharmacokinetic data
Bioavailability Between 35.8 and 60 % in animal studies.
Metabolism Liver
Biological half-life 1.6, 3.0, 4.5, 5.9 and 6 hours. Mouse, Monkey, Rat, Dog and Human respectively.
Excretion 7.0% urine 87.2% faeces
Identifiers
CAS Number 205110-48-1 YesY
PubChem (CID) 5282045
ChemSpider 23258189 N
UNII J0086219X6 YesY
KEGG D02391 N
ChEMBL CHEMBL365528 N
Chemical and physical data
Formula C42H59N3O10
Molar mass 765.931 g/mol
3D model (Jmol) Interactive image
Melting point 211 to 213 °C (412 to 415 °F)
 NYesY (what is this?)  (verify)

Cethromycin, trade name Restanza (initially known as ABT-773[1][2]) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP)[1][3][4][5] and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication.[6] Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

On October 1, 2008 Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.[7]

On December 3, 2008 Advanced Life Sciences announced that this New Drug Application has been accepted for filing by the FDA.[8]

In June 2009, an FDA Anti-Infective Drugs Advisory Committee review found insufficient evidence for cethromycin efficacy in treatment of community acquired pneumonia, as the Phase 3 clinical trial followed standards that were updated after the clinical trial but three months prior to review. The committee did, however, find the drug safe to use.[9]

References

  1. 1 2 Lawrence LE (June 2001). "ABT-773 (Abbott Laboratories)". Current Opinion in Investigational Drugs. 2 (6): 766–72. PMID 11572654.
  2. ↑ Dougherty TJ, Barrett JF (February 2001). "ABT-773: a new ketolide antibiotic". Expert Opinion on Investigational Drugs. 10 (2): 343–51. doi:10.1517/13543784.10.2.343. PMID 11178346.
  3. ↑ Zhanel GG, Hisanaga T, Nichol K, Wierzbowski A, Hoban DJ (November 2003). "Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae". Expert Opinion on Emerging Drugs. 8 (2): 297–321. doi:10.1517/14728214.8.2.297. PMID 14661991.
  4. ↑ Reinert RR (June 2004). "Clinical efficacy of ketolides in the treatment of respiratory tract infections". The Journal of Antimicrobial Chemotherapy. 53 (6): 918–27. doi:10.1093/jac/dkh169. PMID 15117934.
  5. ↑ Hammerschlag MR, Sharma R (March 2008). "Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections". Expert Opinion on Investigational Drugs. 17 (3): 387–400. doi:10.1517/13543784.17.3.387. PMID 18321237.
  6. ↑ Cethromycin - Advanced Life Sciences Archived April 20, 2008, at the Wayback Machine.
  7. ↑ Cethromycin New Drug Application
  8. ↑ Cethromycin New Drug Application accepted for filing by FDA
  9. ↑ Advanced Life Sciences Holdings, Inc. "Complete Response Letter for Restanza NDA". Drugs.com. Retrieved 2014-03-26.

Further reading

This article is issued from Wikipedia - version of the 11/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.